|
Post by savzak on Jun 10, 2015 10:48:26 GMT -5
Probably early July for print advertising.
|
|
|
Post by savzak on Jun 10, 2015 10:58:02 GMT -5
Matt: Initially DTC will be print and web based. Money is budgeted to produce TV spot but the expense is in airing, not producing. TV is being considered and money is allocated for production.
|
|
|
Post by savzak on Jun 10, 2015 11:08:21 GMT -5
SNY is clearly interested in taking Afrezza to a lot of different places but they want a unified expansion strategy. Expect SNY to come to MNKD this summer with that strategy.
|
|
|
Post by savzak on Jun 10, 2015 11:09:36 GMT -5
Remaining milestones are mostly sales oriented. There are a couple based on launching in foreign jurisdictions and one related to production. The rest are all sales related.
Matt: "We do expect to get all those milestones; the question is how rapidly."
|
|
|
Post by savzak on Jun 10, 2015 11:11:43 GMT -5
Regarding convertible debt. We have a lot of options. Volatility makes it hard to select the best options. Matt: "I can virtually guarantee there will not be a secondary offering". The dilution from this instrument has already been factored in.
|
|
|
Post by nemzter on Jun 10, 2015 11:14:47 GMT -5
CAPEX - No more spending on additional lines this year
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 10, 2015 11:17:46 GMT -5
discussions with potential external customers
|
|
|
Post by dstevenson on Jun 10, 2015 11:22:27 GMT -5
External customer?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 10, 2015 11:37:05 GMT -5
external partners for other TS applications
|
|
|
Post by dreamboatcruise on Jun 10, 2015 11:37:36 GMT -5
I couldn't make the call. Did either formulary access or spirometry issue get questioned or addressed?
|
|
|
Post by eddiemoy on Jun 10, 2015 11:45:33 GMT -5
anyone remember what were the terms of the opt out? sny can only give notice starting early next year? then there is a 3 month period? need to listen to that again...
will know which way they will go by november i think...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 10, 2015 11:55:13 GMT -5
The word "hopefully" was used too many times to suit me.
|
|
|
Post by jpg on Jun 10, 2015 12:08:14 GMT -5
The word "hopefully" was used too many times to suit me. Tough crowd... What is he supposed to say about future events? Certainly and get sued? Probably and sound insecure? Maybe and it come across as hedging to much? You certainly cannot be accused of being a glass half full or more type of guy...
|
|
|
Post by scottiemac on Jun 10, 2015 12:21:51 GMT -5
Their crystal ball is in the shop for repairs, lol.
Really, what more can they say? MNKD hands are tied by SNY with details about many things we'd like to know, and other issues are no longer the purview of MNKD (marketing, sales etc.) Projecting into the future is a fool's action - if you announce a set date or volume of sales expected or number of patients getting scripts -- any hard numbers -- you get hammered one way or the other if you fall short, or even if results are better than expected (e.g. being accused of deliberately low-balling.)
There were plenty of positives in the webcast:
pediatric clinical trials begin next quarter;
print & web DTC are weeks away;
money is allocated for TV advertising production and they are looking at possible airing late in the year;
repeating no dilution re August notes;
within 6-9 months the pricing will be reviewed (for move from Tier 3 to Tier 2) and most restrictions such as prior authorizations will fall away or diminish to the norm of once a year instead of with each refill - this is usual for new scripts btw;
many endos buying spirometers because they are reimbursable and they don't want to send patients to pulmonary labs who will over-test (and get paid for it) and they pay for themselves within a few months;
Sanofi is developing a worldwide plan rather than piecemeal, (many countries use the same standards as the FDA and can easily add Afrezza to their formularies while others like Japan and China many require additional clinical trials);
they are looking at label expansion beyond initial restrictions.
|
|
|
Post by tchalaa on Jun 10, 2015 12:22:24 GMT -5
|
|